Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...
The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...
Here are some of the major companies whose stocks moved on the week’s news.
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...